Prescription Drug Information: Fluoxetine Hydrochloride (Page 7 of 11)
Incidence in Major Depressive Disorder, OCD, Bulimia, and Panic Disorder Placebo-Controlled Clinical Trials (excluding data from extensions of trials)
Table 2 enumerates the most common treatment-emergent adverse events associated with the use of fluoxetine (incidence of at least 5% for fluoxetine and at least twice that for placebo within at least one of the indications) for the treatment of major depressive disorder, OCD, and bulimia in U.S. controlled clinical trials and panic disorder in U.S. plus non-U.S. controlled trials. Table 3 enumerates treatment-emergent adverse events that occurred in 2% or more patients treated with fluoxetine and with incidence greater than placebo who participated in U.S. major depressive disorder, OCD, and bulimia controlled clinical trials and U.S. plus non-U.S. panic disorder controlled clinical trials. Table 3 provides combined data for the pool of studies that are provided separately by indication in Table 2.
| 1 Includes U.S. data for major depressive disorder, OCD, bulimia, and panic disorder clinical trials, plus non-U.S. data for panic disorder clinical trials. †Denominator used was for males only (N=690 fluoxetine major depressive disorder; N=410 placebo major depressive disorder; N=116 fluoxetine OCD; N=43 placebo OCD; N=14 fluoxetine bulimia; N=1 placebo bulimia; N=162 fluoxetine panic; N=121 placebo panic). -Incidence less than 1% | ||||||||
| Table 2 Most Common Treatment-Emergent Adverse Events: Incidence in Major Depressive Disorder, OCD, Bulimia, and Panic Disorder Placebo-Controlled Clinical Trials 1 | ||||||||
| Percentage of Patients Reporting Event | ||||||||
| Major Depressive Disorder | OCD | Bulimia | Panic Disorder | |||||
| Body System/ Adverse Event | Fluoxetine (N=1728) | Placebo (N=975) | Fluoxetine (N=266) | Placebo (N=89) | Fluoxetine (N=450) | Placebo (N=267) | Fluoxetine (N=425) | Placebo (N=342) |
| Body as a Whole | ||||||||
| Asthenia | 9 | 5 | 15 | 11 | 21 | 9 | 7 | 7 |
| Flu Syndrome | 3 | 4 | 10 | 7 | 8 | 3 | 5 | 5 |
| Cardiovascular System | ||||||||
| Vasodilatation | 3 | 2 | 5 | – | 2 | 1 | 1 | – |
| Digestive System | ||||||||
| Nausea | 21 | 9 | 26 | 13 | 29 | 11 | 12 | 7 |
| Diarrhea | 12 | 8 | 18 | 13 | 8 | 6 | 9 | 4 |
| Anorexia | 11 | 2 | 17 | 10 | 8 | 4 | 4 | 1 |
| Dry Mouth | 10 | 7 | 12 | 3 | 9 | 6 | 4 | 4 |
| Dyspepsia | 7 | 5 | 10 | 4 | 10 | 6 | 6 | 2 |
| Nervous System | ||||||||
| Insomnia | 16 | 9 | 28 | 22 | 33 | 13 | 10 | 7 |
| Anxiety | 12 | 7 | 14 | 7 | 15 | 9 | 6 | 2 |
| Nervousness | 14 | 9 | 14 | 15 | 11 | 5 | 8 | 6 |
| Somnolence | 13 | 6 | 17 | 7 | 13 | 5 | 5 | 2 |
| Tremor | 10 | 3 | 9 | 1 | 13 | 1 | 3 | 1 |
| Libido decreased | 3 | – | 11 | 2 | 5 | 1 | 1 | 2 |
| Abnormal dreams | 1 | 1 | 5 | 2 | 5 | 3 | 1 | 1 |
| Respiratory System | ||||||||
| Pharyngitis | 3 | 3 | 11 | 9 | 10 | 5 | 3 | 3 |
| Sinusitis | 1 | 4 | 5 | 2 | 6 | 4 | 2 | 3 |
| Yawn | – | – | 7 | – | 11 | – | 1 | – |
| Skin and Appendages | ||||||||
| Sweating | 8 | 3 | 7 | – | 8 | 3 | 2 | 2 |
| Rash | 4 | 3 | 6 | 3 | 4 | 4 | 2 | 2 |
| Urogenital System | ||||||||
| Impotence† | 2 | – | – | – | 7 | – | 1 | – |
| Abnormal ejaculation† | – | – | 7 | – | 7 | – | 2 | 1 |
| 1 Includes U.S data for major depressive disorder, OCD, bulimia, and panic disorder clinical trials, plus non-U.S. data for panic disorder clinical trials. 2 Included are events reported by at least 2% of patients taking fluoxetine, except the following events, which had an incidence on placebo ≥fluoxetine (major depressive disorder, OCD, bulimia, and panic disorder combined): abdominal pain, abnormal dreams, accidental injury, back pain, cough increased, major depressive disorder (includes suicidal thoughts), dysmenorrhea, infection, myalgia, pain, paresthesia, pharyngitis, rhinitis, sinusitis. – Incidence less than 1% | ||
| Table 3 Treatment-Emergent Adverse Events; Incidence in Major Depressive Disorder, OCD, Bulimia, and Panic Disorder Placebo-Controlled Clinical Trials 1 | ||
| Percentage of Patients Reporting Event | ||
| Major Depressive Disorder, OCD, Bulimia, and Panic Disorder Combined | ||
| Body System/Adverse Event 2 | Fluoxetine (N=2869) | Placebo (N=1673) |
| Body as a Whole | ||
| Headache | 21 | 19 |
| Asthenia | 11 | 6 |
| Flu syndrome | 5 | 4 |
| Fever | 2 | 1 |
| Cardiovascular System | ||
| Vasodilatation | 2 | 1 |
| Digestive System | ||
| Nausea | 22 | 9 |
| Diarrhea | 11 | 7 |
| Anorexia | 10 | 3 |
| Dry Mouth | 9 | 6 |
| Dyspepsia | 8 | 4 |
| Constipation | 5 | 4 |
| Flatulence | 3 | 2 |
| Vomiting | 3 | 2 |
| Metabolic and Nutritional Disorders | ||
| Weight loss | 2 | 1 |
| Nervous System | ||
| Insomnia | 19 | 10 |
| Nervousness | 13 | 8 |
| Anxiety | 12 | 6 |
| Somnolence | 12 | 5 |
| Dizziness | 9 | 6 |
| Tremor | 9 | 2 |
| Libido decreased | 4 | 1 |
| Thinking abnormal | 2 | 1 |
| Respiratory System | ||
| Yawn | 3 | – |
| Skin and Appendages | ||
| Sweating | 7 | 3 |
| Rash | 4 | 3 |
| Pruritus | 3 | 2 |
| Special Senses | ||
| Abnormal vision | 2 | 1 |
RxDrugLabels.com provides trustworthy package insert and label information about marketed prescription drugs as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by RxDrugLabels.com. Every individual prescription drug label and package insert entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.
https://rxdruglabels.com/lib/rx/rx-meds/fluoxetine-hydrochloride/page/7/